Skip to Main Content
Table I.

Pathogenic IFN-γ–deficient T cells induce atypical EAE

Injected cells
WT-IL12–treated
 cells
WT-IL23–treated
 cells
IFN-γ KO-IL12–
 treated cells
IFN-γ KO-IL23–treated
 cells
Incidence of disease 5/5 5/5 14/15 15/15 
Incidence of limb dysfunction 5/5 5/5 5/15 2/15 
Incidence of flaccid paralysis 5/5 5/5 0/15 0/15 
Incidence of dystonia 0/5 0/5 5/15 2/15 
Mean day of onset of clinical signs of limb dysfunction 7.6 ± 0.6 20.8 ± 1.5 13.4 ± 4.2 9.0 ± 0 
Mean peak limb dysfunction clinical score 2.5 ± 0 3.8 ± 0.5 1.5 ± 0.7 1.0 ± 0 
Incidence of non-classical EAE 0/5 0/5 14/15 15/15 
Mean day of onset of clinical signs of non-classical EAE NA NA 14.4 ± 4.2 13.1 ± 3.4 
Vertigo 0/5 0/5 11/14 12/15 
Ataxia 0/5 0/5 9/14 9/15 
Injected cells
WT-IL12–treated
 cells
WT-IL23–treated
 cells
IFN-γ KO-IL12–
 treated cells
IFN-γ KO-IL23–treated
 cells
Incidence of disease 5/5 5/5 14/15 15/15 
Incidence of limb dysfunction 5/5 5/5 5/15 2/15 
Incidence of flaccid paralysis 5/5 5/5 0/15 0/15 
Incidence of dystonia 0/5 0/5 5/15 2/15 
Mean day of onset of clinical signs of limb dysfunction 7.6 ± 0.6 20.8 ± 1.5 13.4 ± 4.2 9.0 ± 0 
Mean peak limb dysfunction clinical score 2.5 ± 0 3.8 ± 0.5 1.5 ± 0.7 1.0 ± 0 
Incidence of non-classical EAE 0/5 0/5 14/15 15/15 
Mean day of onset of clinical signs of non-classical EAE NA NA 14.4 ± 4.2 13.1 ± 3.4 
Vertigo 0/5 0/5 11/14 12/15 
Ataxia 0/5 0/5 9/14 9/15 

MOG35-55-specific T cell lines were generated in either C57BL/6 (WT) or IFN-γ–deficient (IFN-γ KO) mice. T cell lines were produced in the presence either of IL-12 or IL-23+TGF-β+IL-6+anti–IFN-γ as described in Materials and methods. The T cell lines were then injected i.v. Mice were examined over time for clinical signs of limb dysfunction, vertigo/disequilibrium, and ataxia. Results are representative of two separate experiments. Results are shown ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal